Results 91 to 100 of about 349,440 (263)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Using Palliative Care Needs Rounds in the UK for care home staff and residents: an implementation science study

open access: yesHealth and Social Care Delivery Research
Background Care home residents often lack access to end-of-life care from specialist palliative care providers. Palliative Care Needs Rounds, developed and tested in Australia, is a novel approach to addressing this.
Liz Forbat   +10 more
doaj   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola   +12 more
wiley   +1 more source

Recommendations for improving accessibility of digital health interventions for cardiometabolic disease for ethnically diverse populations

open access: yesDigital Health
Digital health interventions (DHIs), such as apps, websites and wearables, are being presented as solutions or enablers to manage the burden of cardiometabolic disease in healthcare. However, the potential benefits of DHIs may not be reaching the most in-
Mel Ramasawmy   +12 more
doaj   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Perceptions of vision care following neurological impairment: a qualitative study

open access: yesBMC Health Services Research
Background Visual impairment is a common consequence of neurological impairments, and can impact a person’s ability to undertake everyday tasks, affecting their confidence and mental health.
Kerry Hanna   +3 more
doaj   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

open access: yesMolecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken   +7 more
wiley   +1 more source

Co-developing an intervention to facilitate safe and early transition to neonatal home care for very preterm infants: a mixed-method study evaluating the impact of patient and public involvement

open access: yesResearch Involvement and Engagement
Background Very preterm born infants face elevated risks of adverse neurodevelopmental outcomes, with prolonged hospitalisation associated with poorer cognitive, motor, and language development.
Sofia Arwehed   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy